- Report
- November 2025
- 184 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- February 2026
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- October 2025
- 160 Pages
Global
From €2947EUR$3,358USD£2,549GBP
€3467EUR$3,950USD£2,999GBP
- Report
- August 2025
- 193 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- August 2025
- 180 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- February 2026
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- January 2026
- 150 Pages
Global
From €4257EUR$4,850USD£3,682GBP
- Report
- March 2026
- 136 Pages
Global
From €3510EUR$3,999USD£3,036GBP
- Report
- January 2026
- 190 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 199 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- August 2025
- 194 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- August 2025
- 185 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- August 2025
- 186 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- August 2025
- 199 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- May 2026
- 177 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 180 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 182 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 182 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 180 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 184 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP

The Cell Free DNA (cfDNA) market is a subset of the genomics industry that focuses on the analysis of circulating DNA fragments in the bloodstream. It is used to detect genetic abnormalities, such as chromosomal aneuploidy, and to monitor cancer progression. cfDNA testing is also used to detect fetal genetic abnormalities during pregnancy.
The cfDNA market is expected to grow rapidly in the coming years, driven by increasing demand for non-invasive prenatal testing and the development of new technologies. The market is also expected to benefit from the increasing availability of cfDNA testing kits and the growing awareness of its potential applications.
Notable companies in the cfDNA market include Illumina, Thermo Fisher Scientific, Qiagen, Natera, and Guardant Health. Show Less Read more